Research graph
References from Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction–Associated Steatotic Liver Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
10.1097/hep.0000000000000520 · 2023 · External reference
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
10.1097/hep.0000000000000004 · 2023 · External reference
Metabolic dysfunction-associated steatotic liver disease in adults: a review.
10.1001/jama.2025.19615 · 2026 · External reference
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
10.1038/nrgastro.2017.109 · 2018 · External reference
Epidemiology of chronic liver diseases in the USA in the past three decades.
10.1136/gutjnl-2019-318813 · 2020 · External reference
Nonalcoholic fatty liver disease in lean individuals in the United States.
10.1097/md.0b013e3182779d49 · 2012 · External reference
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.
10.1002/hep.28697 · 2017 · External reference
Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy.
10.1038/ajg.2015.235 · 2015 · External reference
New trends on obesity and NAFLD in Asia.
10.1016/j.jhep.2017.06.003 · 2017 · External reference
Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver.
10.1038/ajg.2016.318 · 2017 · External reference
The impact of PNPLA3 rs738409 genetic polymorphism and weight gain =10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals.
10.1371/journal.pone.0140427 · 2015 · External reference
Liver fat in the metabolic syndrome.
10.1210/jc.2007-0482 · 2007 · External reference
Recent insights into the pathogenesis of nonalcoholic fatty liver disease.
10.1146/annurev-pathol-020117-043617 · 2018 · External reference
Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity.
10.1016/j.cgh.2017.04.045 · 2017 · External reference
Abdominal obesity and metabolic syndrome.
10.1038/nature05488 · 2006 · External reference
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study.
10.1002/hep4.1124 · 2017 · External reference
Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
10.1111/apt.14401 · 2018 · External reference
Non-alcoholic fatty liver disease in lean individuals.
10.1016/j.jhepr.2019.08.002 · 2019 · External reference
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
10.1002/hep.27368 · 2015 · External reference
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
10.1002/hep.24268 · 2011 · External reference
Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
10.1053/j.gastro.2020.01.043 · 2020 · External reference
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
10.1002/hep.21178 · 2006 · External reference
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline.
10.1097/hep.0000000000000842 · 2025 · External reference
Noninvasive assessment of liver fibrosis.
10.1056/nejmra2403308 · 2025 · External reference
Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline.
10.1097/hep.0000000000000852 · 2025 · External reference
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
10.1097/hep.0000000000000323 · 2023 · External reference
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants.
10.1001/jama.2024.21972 · 2025 · External reference
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
10.1007/s10620-013-2743-5 · 2013 · External reference
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
10.1002/hep.20701 · 2005 · External reference
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.
10.1002/hep.24127 · 2011 · External reference
Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease guidelines 2017—part 1: definition, risk factors and assessment.
10.1111/jgh.13857 · 2018 · External reference
AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review.
10.1053/j.gastro.2022.06.023 · 2022 · External reference
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
10.1161/circulationaha.109.192644 · 2009 · External reference
Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.
10.1038/ajg.2016.453 · 2017 · External reference
Reappraisal of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population.
10.3389/fmed.2022.1024836 · 2022 · External reference
EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update.
10.1016/j.jhep.2021.05.025 · 2021 · External reference
Baveno VII—renewing consensus in portal hypertension.
10.1016/j.jhep.2021.12.022 · 2022 · External reference
Global performance of non-invasive tests in MASLD: insights from the G-MASLD study.
10.1097/hep.0000000000001564 · 2026 · External reference
Predictors of fibrosis, clinical events and mortality in MASLD: data from the Global-MASLD study.
10.1097/hep.0000000000001617 · 2026 · External reference
Diagnostic accuracy of non-invasive tests for MASLD across age, type 2 diabetes, and obesity subgroups: a multinational study.
10.1016/j.cgh.2026.01.016 · 2026 · External reference
Association of genetic variations with NAFLD in lean individuals.
10.1111/liv.15078 · 2022 · External reference
Lean nonalcoholic fatty liver disease and sarcopenia.
10.3389/fendo.2023.1217249 · 2023 · External reference
Genetic predisposition in nonalcoholic fatty liver disease.
10.3350/cmh.2016.0109 · 2017 · External reference
Impact of PNPLA3 in lean individuals and in cryptogenic steatotic liver disease.
10.1111/liv.16164 · 2025 · External reference
Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review.
10.21037/tgh-23-31 · 2023 · External reference
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
10.1007/s12072-021-10200-y · 2021 · External reference
Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?
10.3390/biology11081237 · 2022 · External reference
NAFLD/MASLD and the gut-liver axis: from pathogenesis to treatment options.
10.3390/metabo14070366 · 2024 · External reference
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies.
10.3389/fnut.2023.1110536 · 2023 · External reference
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index.
10.1111/j.1365-2036.2011.04668.x · 2011 · External reference
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
10.1016/j.jhep.2017.07.027 · 2017 · External reference
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.
10.1002/hep4.1054 · 2017 · External reference
Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges.
10.3390/biomedicines9101346 · 2021 · External reference
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.
10.1056/nejmoa2309000 · 2024 · External reference
Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial.
10.1111/apt.18331 · 2024 · External reference
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
10.1002/hep.28785 · 2016 · External reference
Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease.
10.1016/j.cld.2023.01.007 · 2023 · External reference
Metabolic dysfunction-associated steatotic liver disease: global epidemiology, patient-reported outcomes, and economic impact.
10.1016/j.cld.2026.01.001 · 2026 · External reference
